Compare · LSTA vs VMD
LSTA vs VMD
Side-by-side comparison of Lisata Therapeutics Inc. (LSTA) and Viemed Healthcare Inc. (VMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both LSTA and VMD operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- VMD is the larger of the two at $371.4M, about 32.1x LSTA ($11.6M).
- LSTA has hit the wire 9 times in the past 4 weeks while VMD has been quiet.
- VMD has more recent analyst coverage (2 ratings vs 0 for LSTA).
- Company
- Lisata Therapeutics Inc.
- Viemed Healthcare Inc.
- Price
- $1.07+0.94%
- $9.49-2.77%
- Market cap
- $11.6M
- $371.4M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 9
- 0
- Recent ratings
- 0
- 2
Viemed Healthcare Inc.
Viemed Healthcare, Inc., through its subsidiaries, provides in-home durable medical equipment and post-acute respiratory healthcare services to patients in the United States. The company offers respiratory services and related equipment, including non-invasive ventilators; bi-level, continuous, and automatic continuous positive airway pressure (PAP) machines; and oxygen therapy, as well as services of respiratory therapists; and respiratory disease management, neuromuscular care, and oxygen therapy services. It also provides in-home sleep apnea testing services to determine the existence of sleep apnea at home. In addition, the company leases non-invasive and invasive ventilators, PAP machines, percussion vests, oxygen concentrator units, and other respiratory equipment, as well as sells medical equipment and/or patient medical services. Further, it provides therapy and counseling to patients in their homes using its technology. The company was founded in 2006 and is headquartered in Lafayette, Louisiana.
Latest LSTA
- SEC Form 3 filed by Lisata Therapeutics Inc.
- SEC Form 8-K filed by Lisata Therapeutics Inc.
- Lisata Therapeutics Appoints Jeff Farrow to Board of Directors
- Lisata Therapeutics Announces New Method of Use Patent Granted for Certepetide in the Treatment of Pancreatic Cancer and Other Solid Tumors
- SEC Form PRE 14A filed by Lisata Therapeutics Inc.
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly
- SEC Form D filed by Lisata Therapeutics Inc.
- New insider Love Ted W claimed ownership of 19,260 shares (SEC Form 3)
- New insider Lehrer-Graiwer Joshua claimed ownership of 27,808 shares (SEC Form 3)
- Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces Upcoming Late-Breaking Presentation of MAR001 Clinical Data at the American Heart Association Scientific Sessions 2026
Latest VMD
- Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
- Barrington Research initiated coverage on Viemed Healthcare with a new price target
- Viemed Healthcare Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Director Heltz Sabrina converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 22% to 82,520 units (SEC Form 4)
- Director Dobbs Randy E. converted options into 20,954 shares and returned $37,468 worth of shares to the company (4,191 units at $8.94), increasing direct ownership by 13% to 142,253 units (SEC Form 4)
- Director Kaushal Nitin converted options into 18,786 shares, increasing direct ownership by 13% to 161,361 units (SEC Form 4)
- Director Smokoff Timothy converted options into 18,786 shares and returned $33,588 worth of shares to the company (3,757 units at $8.94), increasing direct ownership by 20% to 90,547 units (SEC Form 4)
- SEC Form S-8 filed by Viemed Healthcare Inc.
- SEC Form 10-Q filed by Viemed Healthcare Inc.
- Viemed Healthcare Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits